Multi-Strain Probiotic Composition for Broad IBS Symptom Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing probiotic treatments for irritable bowel syndrome (IBS) are strain-specific and often ineffective in addressing all major symptoms, with varying results due to different probiotic and prebiotic components and patient subsets, lacking a broad activity that improves symptoms across IBS subtypes.
Innovation Solution
A pharmaceutical composition comprising specific strains of probiotic bacteria, including Lactobacillus helveticus, Lacticaseibacillus rhamnosus, Lacticaseibacillus casei, Lactiplantibacillus plantarum, Lactococcus lactis, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium bifidum, and Streptococcus thermophilus, effectively reduces abdominal pain, flatulence, dissatisfaction with bowel habits, and improves quality of life in IBS patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-strain or multi-strain probiotics are used to treat IBS, then some symptomatic aspects may be improved, but no broad activity is achieved to improve all major symptoms across IBS subtypes
Solution Approach 1:
The patent combines nine different probiotic strains from five genera (Lactobacillus, Lacticaseibacillus, Lactococcus, Bifidobacterium, and Streptococcus) into a single pharmaceutical composition. This multi-strain approach merges the potential benefits of each individual strain to achieve broad-spectrum effectiveness across all major IBS symptoms and subtypes, resolving the contradiction between targeted symptom relief and broad adaptability.
Solution Approach 2:
The pharmaceutical composition is designed to universally address all major symptoms of IBS including abdominal pain, bloating, flatulence, and stool consistency issues across different IBS subtypes (IBS-D, IBS-C, IBS-M). The multi-strain probiotic formulation provides multi-functionality by simultaneously targeting multiple symptom pathways, achieving both reliability in symptom improvement and versatility across patient populations.
2Adaptability or versatility
If different probiotic and prebiotic components are used in clinical trials, then various patient subsets may be studied, but results vary and therapeutic value is difficult to determine
Solution Approach 1:
The patent specifies precise parameters for the probiotic composition including exact strain identities (e.g., Lactobacillus helveticus, Lacticaseibacillus rhamnosus), colony forming units per capsule (4.5 x 10^9 CFU), and daily dosage (one capsule). These standardized parameters enable consistent therapeutic effects across different patient subsets while allowing for precise measurement and comparison of therapeutic value in clinical settings.
3Manufacturing precision
If probiotic treatments are strain-specific, then targeted effects may be achieved, but effectiveness is limited to specific symptoms or patient groups
Solution Approach 1:
The patent creates a composite probiotic formulation containing nine different bacterial strains from five genera, each with specific manufacturing precision and identified strains. This composite approach maintains the strain-specific precision of individual components while achieving comprehensive symptom coverage through the synergistic combination of multiple strains with different mechanisms of action, thereby resolving the contradiction between specificity and overall effectiveness.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a pharmaceutical composition for treating IBS.